



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/919,224	07/30/2001	Thomas J. Schall	019934-001710US	5559

20350 7590 03/09/2004

TOWNSEND AND TOWNSEND AND CREW, LLP
TWO EMBARCADERO CENTER
EIGHTH FLOOR
SAN FRANCISCO, CA 94111-3834

EXAMINER

BELYAVSKIY, MICHAEL A

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 03/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/919,224

Applicant(s)

SCHALL ET AL.

Examiner

Michail A Belyavskiy

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 15 January 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 21-38 and 44-61 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 21-38 and 44-61 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- ☐ Notice of Informal Patent Application (PTO-152)
- ☐ Other: _____

RESPONSE TO APPLICANT'S AMENDMENT

1. Applicant's amendment, filed 1/15/04 is acknowledged.

Claims 21-38 and 44-61 are pending.

Claims 21-38 and 44-61 are under consideration in the instant application.

In view of the amendment, filed 1/15/04 the following rejections remain

2. The following is a quotation of the second paragraph of 35 U.S.C. 112.

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 26 and 46 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 26 and 46 are indefinite and ambiguous in the recitation of "monitoring the patient to detect amelioration of a symptom associated with the immune disorder". The characteristics and metes and bounds of "a symptom" are unclear, indefinite, not defined by the claim and the specification does not provide a standard for ascertaining what "symptom to monitor".

Applicant's arguments, 1/15/04 have been fully considered, but have not been found convincing.

Applicant asserts that the specification lists symptoms for a number of different immune diseases.

Contrary to applicant's assertion, it is noted that applicant only disclosed the symptoms of several specific diseases. However, the term "immune disorder" included diseases that not listed by Applicant and metes and bounds of "a symptom" of said non-listed diseases are unclear, indefinite, not defined by the claim and the specification does not provide a standard for ascertaining what "symptom to monitor".

Art Unit: 1644

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 21-38 and 44-61 stand rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of inhibiting proliferation of the peripheral blood mononuclear cells, reducing cytokine production of monocytes and reducing surface expression of classical class I and Class II MHC molecules by monocytes *in vitro*, using rhesus CMV IL-10, does not reasonably provide enablement for: 1) a therapeutic or prophylactic method for treating *any* immune disorder, such as the ones recited in claim 24, or allergic response, as recited in claim 34, or asthma, as recited in claim 35, or leukemia, as recited in claim 38, or *any* chronic inflammatory disease, such as the ones recited in claim 33 or type Th1 immune response to any transplanted graft, for example bone marrow, as recited in claims 36-37, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 21-38 and 50-55 or 2) a therapeutic or prophylactic method for treating *any* inflammatory response, such as the ones recited in claim 49, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 44-49 and 56-61. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims for the same reasons set forth in the previous Office Action, mailed 07/15/03.

Applicant's arguments, filed 1/15/04 have been fully considered, but have not been found convincing.

Applicant asserts that: (i) the law is clear that *in vivo* examples are not required to enable treatment claims. *In vitro* examples are sufficient to constitute working examples, provided they reasonable correlate with the claimed method; (ii) symptoms associates with various immune diseases are known in the art; (iii) one of the ordinary skill in the art could readily identify individuals that could benefit from prophylactic treatment.

The examiner agrees that *in vivo* examples are not required to enable treatment claims and that symptoms associates with various immune diseases are known in the art.

However, the issue raised in the previous Office Action was that the specification does not adequately teach how to effectively use a therapeutic or prophylactic method for treating an immune disorder, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 21-28, 32, 33, 36, 37 and 50-55, or 2) a therapeutic or prophylactic method for treating an inflammatory response, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 44-49 and 56-61. Moreover, no animals were used as model system for the therapeutic or prophylactic method for treating an immune disorder or for treating an inflammatory response, comprising administering a

Art Unit: 1644

pharmaceutically acceptable dose of rhesus CMV IL-10. Since there is no animal model system in the specification to treat an immune disorder, for example GVHD as recited in claim 24, or allergic response, as recited in claim 34, or asthma, as recited in claim 35, or leukemia, as recited in claim 38, or *any* chronic inflammatory disease, for example rheumatoid arthritis as recited in claim 33 or type Th1 immune response to any transplanted graft, for example bone marrow, as recited in claims 36-37, or an inflammatory response, for example chronic inflammatory disease rheumatoid arthritis, as recited in claim 49, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, it is unpredictable how to correlate test tube results with *in vivo* studies. It is the examiner position that the *in vitro* examples provided by the Applicant and that are disclosed on overlapping pages 11 and 12 of the Applicant's arguments, filed 1/15/04 do not correlate with *in vivo* studies. Since the method to treat an immune disorder, for example GVHD as recited in claim 24, or allergic response, as recited in claim 34, or asthma, as recited in claim 35, or leukemia, as recited in claim 38, or *any* chronic inflammatory disease, for example rheumatoid arthritis as recited in claim 33 or type Th1 immune response to any transplanted graft, for example bone marrow, as recited in claims 36-37, or an inflammatory response, for example chronic inflammatory disease rheumatoid arthritis, as recited in claim 49, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, can be species- and model-dependent, it is not clear that reliance on the test tube studies accurately reflects the relative human efficacy of the claimed therapeutic strategy. The specification does not adequately teach how to effectively treat an immune disorder or an inflammatory response comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10.

The specification does not teach how to extrapolate data obtained from *in vitro* studies to the development of effective *in vivo* mammalian including human therapeutic treatment, commensurate in scope with the claimed invention. Lockridge et al. (IDS) teach that CMV IL-10 is a multifunctional cytokines that has various effects on inflammation and cytokine production and that further studies will be necessary to determine its role in the immunopathogenesis. (see entire document, page 278 in particular). Additionally, Bals R., et al., (Infection and Immunity, 1999, v.67, pages 6084-6089) teach that functional studies have been restricted primarily to *in vitro* experiments with purified peptides and do not necessarily reflect the complexity of *in vivo* interaction, such as synergism and antagonism between individual substances (see overlapping pages 6087-6088 in particular). Mountain reviews in Trends Biotechnol (18:119-128, 2000) that while much progress has been made in the field of gene therapy, developing effective gene therapies is much more demanding than originally anticipated (e.g., pg 120, middle); and that most of the difficulty lies with the development of effective vectors since the vectors in use all have both advantages and disadvantages (e.g., Table 4). Additionally, an effective protocol to treat an immune disorder or an inflammatory response comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, is subject to a number of factors which enter the picture beyond simply the administration of the therapeutic composition in an acceptable formulation. Demonstrating that contacting PBMCs with rhesus CMV IL-10 inhibits PBMC proliferation and cytokine production and reduces monocytes surface expression of classical class I and class II MHC cannot alone support the predictability of a pharmaceutically acceptable dose of rhesus CMV IL-10 for a therapeutic or prophylactic method for treating an immune disorder or an inflammatory response through

Art Unit: 1644

administration of the appropriate formulation. Van Noort et al. (International Review of Cytology, 1998) indicate factors that effect autoimmune disease such as genetic, environmental and hormonal (Page 176, Paragraph 3). The ability of a host to suppress an immune disorder or an inflammatory response will vary depending upon factors such as the condition of the host and burden of disease.

The specification does not provide sufficient teaching as to how it can be assessed that treatment of an immune disorder, for example GVHD as recited in claim 24, or allergic response, as recited in claim 34, or asthma, as recited in claim 35, or leukemia, as recited in claim 38, or any chronic inflammatory disease, for example rheumatoid arthritis as recited in claim 33 or type Th1 immune response to any transplanted graft, for example bone marrow, as recited in claims 36-37, or an inflammatory response, for example chronic inflammatory disease rheumatoid arthritis, as recited in claim 49, was achieved after the administering of a pharmaceutically acceptable dose of rhesus CMV IL-10.

It is also noted that the issue raised in the previous Office Action was not about identifying individuals that could benefit from prophylactic treatment. As was stated in the Previous Office Action mailed on 07/15/03 the burden of enabling prophylactic an immune disorder or an inflammatory response (i.e. the need for additional testing) would be greater than that of enabling a treatment due to the need to screen those humans susceptible to such diseases and the difficulty of proof that the administration of the drug was the agent that acted to prevent the condition. Further, the specification does not provide guidance as to how one skilled in the art would go about screening those patients susceptible to an immune disorder or an inflammatory response within the scope of the presently claimed invention. Nor is guidance provided as to a specific protocol to be utilized in order to prove the efficacy of the presently claimed compounds in preventing these disease states. Accordingly, undue experimentation is necessary to determine screening and testing protocols to demonstrate the efficacy of the presently claimed invention.

Thus, Applicant has not provided sufficient guidance to enable one skill in the art to use claimed:

1) a therapeutic or prophylactic method for treating *any* immune disorder, such as the ones recited in claim 24, or allergic response, as recited in claim 34, or asthma, as recited in claim 35, or leukemia, as recited in claim 38, or *any* chronic inflammatory disease, such as the ones recited in claim 33 or type Th1 immune response to any transplanted graft, for example bone marrow, as recited in claims 36-37, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 21-38 and 50-55 or 2) a therapeutic or prophylactic method for treating *any* inflammatory response, such as the ones recited in claim 49, comprising administering a pharmaceutically acceptable dose of rhesus CMV IL-10, as claimed in claims 44-49 and 56-61 in manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement. *In re Fisher*, 166 USPQ 18(CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute.

Art Unit: 1644

In view of the quantity of experimentation necessary, the unpredictability of the art, the lack of sufficient guidance in the specification, the limited working examples, and the limited amount of direction provided given the breadth of the claims, it would take undue trials and errors to practice the claimed invention.

The following new ground of rejection are necessitated by the amendment filed 1/15/03

6. The following is a quotation of the second paragraph of 35 U.S.C. 112.

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claim 46 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 46 is indefinite and ambiguous in the recitation of "symptom associated with the immune disorder...". There is no antecedent basis for this limitation in the base claim 44. The base claim 44 only recited an inflammatory response.

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1644

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskiy whose telephone number is 571/ 272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571/ 272-0841 .

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michail Belyavskiy, Ph.D.
Patent Examiner
Technology Center 1600
February 26, 2004


CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600